That’s a wrap on QICC’s 20th anniversary. Thank you to everyone who joined us—for the science, the conversations, and the friendship.
See you next year on November 18.
Hyun Jin Ahn:QICC2026 AI Daily News What makes a study editor-worthy? Editor’s Picks, 4 JACC: Asia associate editors explain why impact isn’t only about citations: unmet clinical needs, fresh angles on old questions & real-world evidence matter.
https://t.co/sLO3vSzvUV
At #QICC2026, the JACC:Asia Pulse team doesn’t just report — they host QICC AI Daily News, deliver daily previews & wrap up the key news. 🎙️
Welcome to QICC 2026.
20 years of science, connection & friendship. #QICC2026 welcomes 15,000+ registered participants, 3,000+ speakers & 160 international faculty from 26 countries/regions. 60→300+ forums. Rooted in Hangzhou, built with the world. Together, let’s learn, discover & innovate.
QICC turns 20 — and you’re invited. Prof. Filippo Crea welcomes you to Hangzhou in November 2026 for four ESC joint sessions and a world-class cardiovascular program. #QICC2026#ESC#Cardiology 👉 https://t.co/WvI9o2AMds
https://t.co/vSPvIaXDBs @escardio@ehj_ed
Prof. Thomas F. Lüscher, ESC immediate past president, invites you to #QICC2026: 4 joint sessions on CKD & HF guidelines, China epidemiology, AI in CV care & eminent trials. https://t.co/81eCowqh5q
https://t.co/WvI9o2AMds
Filippo Crea (EHJ EiC): China leads EHJ submissions—but fit > volume. Best fit: new actionable target + human samples/cohort at the core, not bench-only. #EHJ#Cardiology
https://t.co/wRIjiLheGs
SINGLE-CLOSURE: one vs two ProGlide devices; primary endpoint 13.1% vs 15.1%, noninferiority met. In selected TAVR patients, one ProGlide is safe and offers more choice. At TCT 2026, most experts would start with one.
#TCT2026 https://t.co/TreR2uj0fM
SINGLE-CLOSURE: A single-ProGlide strategy may be noninferior for a composite of access-site or access-related vascular complications compared to conventional double-ProGlide closure following transfemoral #TAVR.
Read more: https://t.co/rdVMs4UMNJ
#JACC#TCT2026@crfheart
SINGLE-CLOSURE: A single-ProGlide strategy may be noninferior for a composite of access-site or access-related vascular complications compared to conventional double-ProGlide closure following transfemoral #TAVR.
Read more: https://t.co/rdVMs4UMNJ
#JACC#TCT2026@crfheart
Cancer treatment must not come at the cost of the heart.
JACC: CardioOncology Editor-in-Chief Bonnie Ky, Prof. Yue Li & Prof. Yi Zhang face the toughest clinical questions in cardio-oncology: How to de-escalate antiplatelet therapy
https://t.co/pHC0HNcj5C
Prof. William F. Fearon highlights how physiology-guided PCI (e.g., FFR) optimizes stent use & outcomes. He praises FLAVOUR trials for changing global practice. Happy 20th QICC: 20 years, one heart! #QICC#FFR#Cardiology
https://t.co/J5XQJQoEnX
Leading Chinese interventional cardiologist, Dr. Jian’an Wang has been named inaugural Editor-in-Chief of #JACCAsia, the new online open access journal that will begin publishing in early 2021. Read more: https://t.co/hYdZCAMMp4 @JACCJournals
Leading Chinese interventional cardiologist, Dr. Jian’an Wang has been named inaugural Editor-in-Chief of #JACCAsia, the new online open access journal that will begin publishing in early 2021. Read more: https://t.co/IHJsPsg07G #JACCJournals
The ACC is seeking applications for Editor-in-Chief of #JACCAsia, the newest #OpenAccess JACC Journal. As the 1st region-specific CV journal, this new journal will feature the highest quality papers from authors across East Asia. Learn more: https://t.co/8TykTSzIud
Prof. Bon-Kwon Koo: Questions, not indices, drive research. FLAVOUR compares concepts (imaging vs. physiology), not devices. Happy 20th, QICC: 20 years, one heart! #QICC#FLAVOUR#Cardiology https://t.co/tI2zfXIjdf via